Results 71 to 80 of about 126,740 (294)

Lab-on-a-Disc for Liquid Biopsy [PDF]

, 2018
The lab-on-a-disc systems to isolate and detect liquid biopsy markers such as circulating tumor cells (CTCs) and cell-free DNA(cfDNA) or Extracellular vesicles (EVs) are developed and tested with clinical samples such as whole blood or urine from cancer ...
Cho, Yoon-Kyoung
core  

Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS) [PDF]

Liquid biopsy; European liquid biopsy societyBiòpsia líquida; Societat europea de biòpsia líquidaBiopsia líquida; Sociedad europea de biopsia ...
Pantel, Klaus, Stoecklein, Nikolas Hendrik, Hofman, P., Lu, Yong-Jie, Alix-Panabières, Prof Catherine, Lianidou, Evi, Toledo, Rodrigo   +6 more
core   +1 more source

Recent advances in liquid biopsy technologies for cancer biomarker detection [PDF]

, 2022
Gene mutation is associated with cancer and the dissemination of circulating biomarkers through the blood represents a vital transitional step that exemplifies the shift from localized to systemic disease.
Shiddiky, Muhammad JA, Clack, Kimberley, Soda, Narshone   +2 more
core   +1 more source

Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients

Frontiers in Oncology, 2023
IntroductionCirculating tumor DNA (ctDNA) has been increasingly recognized as a promising minimally-invasive biomarker that could identify patients with minimal residual disease and a high risk of recurrence after definitive treatment.
Hiu Ting Chan, Satoshi Nagayama, Satoshi Nagayama, Masumi Otaki, Masumi Otaki, Yoon Ming Chin, Yoon Ming Chin, Yosuke Fukunaga, Masashi Ueno, Yusuke Nakamura, Yusuke Nakamura, Siew-Kee Low   +11 more
doaj   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients

Journal of Translational Medicine, 2018
Background The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified.
Mayte Delgado-Ureña, Francisco G. Ortega, Diego de Miguel-Pérez, Alba Rodriguez-Martínez, Jose L. García-Puche, Hugh Ilyine, Jose A. Lorente, Jose Exposito-Hernandez, M. Carmen Garrido-Navas, Miguel Delgado-Ramirez, M. José Serrano   +10 more
doaj   +1 more source

Liquid biopsy‐based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis

Molecular Oncology, EarlyView.
This schematic outlines the workflow from biomarker identification to duplex MethyLight assay validation for epithelial ovarian cancer diagnosis using cfDNA‐based liquid biopsy. Initial screening of hypermethylated CpG candidates (cg02957270, cg10061138 cg00480298, COL2A1) was performed in tissue using ARMS‐PCR, COBRA, qPCR and image analysis. Selected
Deepa Bisht, Sameer Gupta, Amrita Chaurasia, Manisha Sachan   +3 more
wiley   +1 more source

Liquid Biopsy in Gastrointestinal Stromal Tumor [PDF]

, 2017
Over the past 15 years, gastrointestinal stromal tumors (GISTs) have emerged from a poorly understood neoplasm to a well-defined tumor entity. Starting from 2000, the discovery of gain-of-function mutations involving KIT or PDGFRα (platelet-derived ...
Daniele Fanale, Fanale D, Antonio Russo, Lorena Incorvaia, Le Cesne A, Marta Castiglia, Nadia Barraco, Alex Le Cesne, Barraco N, Badalamenti G, Incorvaia L, Castiglia M, Russo A, Giuseppe Badalamenti   +13 more
core   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source